Overview
Distinguish two pulmonary vascular complications of portal hypertension, confirm each with the right test, and coordinate cardiopulmonary optimisation with liver-transplant decisions.
Hepatopulmonary syndrome (HPS) is a gas-exchange disorder caused by intrapulmonary vascular dilatation and shunting in the setting of liver disease or portal hypertension. Dilated capillaries permit blood to pass too far from alveolar oxygen or too quickly for complete equilibration. Patients develop exertional dyspnoea, cyanosis or low saturation, often worse when upright. Pulse oximetry is a useful prompt, but arterial blood gas analysis, including the alveolar–arterial oxygen gradient, defines the oxygenation defect. Contrast transthoracic echocardiography demonstrates intrapulmonary passage; it does not measure hypoxaemia severity.
Portopulmonary hypertension (PoPH) is a different problem: precapillary pulmonary arterial hypertension in a person with portal hypertension. Pulmonary vascular resistance rises, progressively loading the right ventricle. Exertional breathlessness, fatigue, chest discomfort, presyncope, a loud pulmonary component of the second heart sound and right-heart failure are possible. Cirrhosis itself can produce high cardiac output or fluid overload with raised pulmonary pressure, so right-heart catheterisation is essential to measure mean pulmonary arterial pressure, pulmonary arterial wedge pressure, pulmonary vascular resistance and cardiac output before the label is accepted.